Di John D, Wasserman S S, Torres J R, Cortesia M J, Murillo J, Losonsky G A, Herrington D A, Stürcher D, Levine M M
Division of Geographic Medicine, University of Maryland School of Medicine, Baltimore.
Lancet. 1989 Dec 16;2(8677):1415-8. doi: 10.1016/s0140-6736(89)92033-3.
To examine whether prior immunity against a carrier protein modulates the serological response to injected peptide haptens attached to the same carrier in man, baseline tetanus antitoxin levels in volunteers who received a malaria sporozoite peptide-tetanus toxoid conjugate vaccine were compared with post-vaccination IgM and IgG antibody titres against the sporozoite antigen. In tetanus-vaccinated North American recipients of low doses of conjugate vaccine there were significant dose-dependent negative correlations between these variables, which suggests that epitopic suppression may occur in man. In contrast, Venezuelans living in non-malarious areas and mostly naive to tetanus toxoid showed a notable IgM response to the sporozoite antigen. The findings indicate that epitopic suppression and immune enhancement occur in man, and that the specific immunological responses to conjugate peptide vaccines may be difficult to predict.
为了研究既往针对载体蛋白的免疫是否会调节人体对与同一载体相连的注射肽半抗原的血清学反应，将接受疟疾子孢子肽-破伤风类毒素结合疫苗的志愿者的基线破伤风抗毒素水平与接种疫苗后针对子孢子抗原的IgM和IgG抗体滴度进行了比较。在接种破伤风疫苗的北美低剂量结合疫苗接受者中，这些变量之间存在显著的剂量依赖性负相关，这表明在人体中可能发生表位抑制。相比之下，生活在非疟疾地区且大多未接触过破伤风类毒素的委内瑞拉人对子孢子抗原表现出显著的IgM反应。这些发现表明，表位抑制和免疫增强在人体中都会发生，并且对结合肽疫苗的特异性免疫反应可能难以预测。
